pI: 8.1577 |
Length (AA): 984 |
MW (Da): 110754 |
Paralog Number:
0
Signal peptide: N | GPI Anchor: | Predicted trans-membrane segments: 0
Targets have been classified into druggability groups (DG) according to their druggability score in network driven prioritizations. DGs range from 1 to 5; the higher the group number, the higher the chance of the target to be druggable
Modbase 3D models:
There are 10 models calculated for this protein. More info on
these models, including the
models themselves is available at:
Modbase
Target Beg | Target End | Template | Template Beg | Template End | Identity | Evalue | Model Score | MPQS | zDope |
---|---|---|---|---|---|---|---|---|---|
19 | 110 | 1v9x (A) | 3 | 92 | 28.00 | 0.14 | 0.88 | 0.361596 | 0.3 |
28 | 104 | 2dmj (A) | 15 | 92 | 29.00 | 0 | 0.62 | 0.354852 | 0.25 |
28 | 116 | 1uw0 (A) | 5 | 105 | 27.00 | 0 | 0.42 | 0.201047 | 0.6 |
144 | 257 | 5hzr (A) | 554 | 672 | 40.00 | 0.000000021 | 1 | 0.519954 | -0.24 |
465 | 979 | 1z63 (A) | 554 | 896 | 33.00 | 0 | 1 | 0.223474 | 1.8 |
684 | 735 | 2ecm (A) | 1 | 49 | 49.00 | 0.0074 | 0.83 | 0.431946 | -0.06 |
691 | 735 | 2ysl (A) | 22 | 63 | 29.00 | 0 | 0.78 | 0.347332 | -0.16 |
692 | 735 | 2y43 (A) | 25 | 63 | 31.00 | 0 | 0.91 | 0.410315 | -1.06 |
813 | 979 | 5gn1 (A) | 946 | 1124 | 36.00 | 0 | 1 | 0.685815 | -0.96 |
830 | 930 | 2db3 (A) | 488 | 580 | 27.00 | 0.6 | 0.68 | 0.371742 | -0.21 |
Help me make sense of these data.
A more detailed description of these scores is available at the Modbase Model Evaluation Help Pages, and in the papers referenced therein.
PDB Structures:
Upregulation Percent | Ranking | Stage | Dataset |
---|---|---|---|
Upper 80-100% percentile | Procyclic, Bloodstream Form. | Siegel TN |
Siegel TN | Genome-wide analysis of mRNA abundance in two life-cycle stages of Trypanosoma brucei and identification of splicing and polyadenylation sites. |
Ortholog group members (OG5_130425)
Species | Accession | Gene Product |
---|---|---|
Arabidopsis thaliana | AT1G05120 | Helicase protein with RING/U-box domain |
Babesia bovis | BBOV_III008700 | DNA repair protein rhp16, putative |
Candida albicans | CaO19.10486 | similar to S. cerevisiae repairosome nucleotide excision repair protein (SNF helicase domain) |
Candida albicans | CaO19.2969 | similar to S. cerevisiae repairosome nucleotide excision repair protein (SNF helicase domain) |
Cryptosporidium hominis | Chro.40028 | DNA repair protein rhp16 |
Cryptosporidium parvum | cgd4_140 | Swi2/Snf2 ATpase,Rad16 ortholog |
Leishmania braziliensis | LbrM.25.0620 | DNA repair protein, putative |
Leishmania donovani | LdBPK_250770.1 | DNA repair protein, putative |
Leishmania infantum | LinJ.25.0770 | DNA repair protein, putative |
Leishmania major | LmjF.25.0740 | DNA repair protein, putative |
Leishmania mexicana | LmxM.25.0740 | DNA repair protein, putative |
Neospora caninum | NCLIV_046520 | hypothetical protein |
Oryza sativa | 4343361 | Os07g0511500 |
Plasmodium berghei | PBANKA_1463700 | DNA repair protein rhp16, putative |
Plasmodium falciparum | PF3D7_1250800 | DNA repair protein rhp16, putative |
Plasmodium knowlesi | PKNH_1470800 | DNA repair protein rhp16, putative |
Plasmodium vivax | PVX_101435 | DNA repair protein rhp16, putative |
Plasmodium yoelii | PY00648 | similar nucleotide excision repair proteins-related |
Plasmodium yoelii | PY01231 | SNF2 family N-terminal domain, putative |
Saccharomyces cerevisiae | YBR114W | DNA repair protein RAD16 |
Trypanosoma brucei gambiense | Tbg972.11.750 | DNA repair protein, putative |
Trypanosoma brucei | Tb927.11.750 | DNA repair protein, putative |
Trypanosoma congolense | TcIL3000_0_15260 | DNA repair protein, putative |
Trypanosoma cruzi | TcCLB.506925.140 | DNA repair protein, putative |
Toxoplasma gondii | TGME49_226440 | SWI2/SNF2-containing protein RAD16 |
Gene/Ortholog | Organism | Phenotype | Source Study |
---|---|---|---|
Tb11.03.0400 this record | Trypanosoma brucei | no significant loss or gain of fitness in bloodstream forms (3 days) | alsford |
Tb11.03.0400 this record | Trypanosoma brucei | significant gain of fitness in bloodstream forms (6 days) | alsford |
Tb11.03.0400 this record | Trypanosoma brucei | no significant loss or gain of fitness in procyclic forms | alsford |
Tb11.03.0400 this record | Trypanosoma brucei | no significant loss or gain of fitness in differentiation of procyclic to bloodstream forms | alsford |
PBANKA_1463700 | Plasmodium berghei | Dispensable | plasmo |
TGME49_226440 | Toxoplasma gondii | Essentiality uncertain | sidik |
shigen | Profiling of E. coli Chromosome (PEC) | National Institute of Genetics, Japan |
nmpdr | Genome-scale essentiality datasets from published studies (M. tuberculosis) | National Microbial Pathogen Data Resource |
yeastgenome | Systematic deletion of yeast genes | Saccharomyces Genome Database |
wormbase | C. elegans RNAi experiments | WormBase web site, http://www.wormbase.org, release WS170 |
blattner | Systematic mutagenesis of the E. coli (MG1655) genome | J Bacteriol 2004, 186:4921-4930 |
neb | C. elegans RNAi phenotypes | Data obtained from Wormbase WS150, curated by K. Chaudary and T. Carlow, New England Biolabs |
alsford | High-throughput phenotyping using parallel sequencing of RNA interference targets in the African trypanosome | Genome Res 2011, 21:915-924 |
keio | Systematic single-gene knock-out mutants of E. coli K12 | The Keio Collection |
gerdes | Experimental determination and system-level analysis of essential genes in E. coli MG1655 | Gerdes et al., J Bacteriol. 2003 185:5673-84 |
Affected Entity | Phenotypic quality | Occurs in | Occurs at | Evidence | Observed in | Drugs/Inhibitors |
---|---|---|---|---|---|---|
cell proliferation (GO:0008283) | normal (PATO:0000461) | bloodstream stage trypomastigotes (PLO:0027) | inferred from RNAi experiment (ECO:0000019) | No drug identifiers listed for this gene. | ||
Annotator: | fernan@iib.unsam.edu.ar. | Comment: | normal cell proliferation (no significant loss or gain of fitness) in bloodstream forms (stage 3 days). | References: | 21363968 | |
cell proliferation (GO:0008283) | increased (PATO:0000470) | bloodstream stage trypomastigotes (PLO:0027) | inferred from RNAi experiment (ECO:0000019) | No drug identifiers listed for this gene. | ||
Annotator: | fernan@iib.unsam.edu.ar. | Comment: | increased cell proliferation (significant gain of fitness) in bloodstream forms (stage 6 days). | References: | 21363968 | |
cell proliferation (GO:0008283) | normal (PATO:0000461) | procyclic (PLO:0034) | inferred from RNAi experiment (ECO:0000019) | No drug identifiers listed for this gene. | ||
Annotator: | fernan@iib.unsam.edu.ar. | Comment: | normal cell proliferation (no significant loss or gain of fitness) in differentiation of procyclic to bloodstream forms . | References: | 21363968 |
In TDR Targets, information about phenotypes that are caused by drugs, or by genetic manipulation of cells (e.g. gene knockouts or knockdowns) is manually curated from the literature. These descriptions help to describe the potential of the target for drug development. If no information is available for this gene or if the information is incomplete, this may mean that i) the papers containing this information either appeared after the curation effort for this organism was carried out or they were inadvertently missed by curators; or that ii) the curation effort for this organism has not yet started.
In any case, if you have information about papers containing relevant validation data for this target, please contact us.
1 literature reference was collected for this gene.